Back to Journals » OncoTargets and Therapy » Volume 9

Observational cohort study focused on treatment continuity of patients administered XELOX plus bevacizumab for previously untreated metastatic colorectal cancer

Authors Kotaka M, Ikeda F, Tsujie M, Yoshioka S, Nakamoto Y, Ishii T, Kyogoku T, Kato T, Tsuji A, Kobayashi M

Received 13 January 2016

Accepted for publication 9 May 2016

Published 7 July 2016 Volume 2016:9 Pages 4113—4120


Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 3

Editor who approved publication: Professor Min Li

Masahito Kotaka,1 Fusao Ikeda,2 Masaki Tsujie,3 Shinichi Yoshioka,4 Yoshihiko Nakamoto,5 Takaaki Ishii,6 Takahisa Kyogoku,7 Takeshi Kato,8 Akihito Tsuji,9 Michiya Kobayashi10

1Gastrointestinal Cancer Center, Sano Hospital, Kobe, Hyogo, 2Department of Surgery, Kohka Public Hospital, Koka, Shiga, 3Department of Colorectal Surgery, Sakai City Medical Center, Sakai, Osaka, 4Department of Surgery, Hyogo Prefectural Nishinomiya Hospital, Nishinomiya, Hyogo, 5Department of Surgery, Seikei-kai Chiba Medical Center, Chiba, Chiba, 6Department of Surgery, Kobe-Ekisaikai Hospital, Kobe, Hyogo, 7Department of Surgery, Nishikobe Medical Center, Kobe, Hyogo, 8Department of Colorectal Surgery, Kansai Rosai Hospital, Amagasaki, Hyogo, 9Kagawa University Hospital Cancer Center, Kita-gun, Kagawa, 10Department of Human Health and Medical Sciences, Kochi Medical School, Kochi University, Nangoku, Kochi, Japan

Background: There has been remarkable progress in systemic chemotherapy for metastatic colorectal cancer due to the widespread use of irinotecan, oxaliplatin, anti-vascular endothelial growth factor antibody, and anti-epidermal growth factor receptor antibody. It is important to continue treatment with the optimal combination of these drugs and prolong progression-free survival (PFS) to improve overall survival (OS). We conducted a prospective observational cohort study of 40 patients treated with XELOX plus bevacizumab for previously untreated metastatic colorectal cancer to investigate treatment continuity.
Patients and methods: Eligibility criteria were as follows: 1) histologically confirmed metastatic colorectal cancer; 2) lesions evaluable by imaging; 3) previously untreated; 4) suitable condition to receive XELOX plus bevacizumab; and 5) written informed consent. Outcomes were treatment continuity, overall response rate, resection rate, liver resection rate, time to treatment failure, PFS, and OS. Forty patients were enrolled and followed up for 2 years.
Results: Between July 2010 and June 2012, 40 patients were enrolled. The median number of treatment cycles was 7.5, and the reasons for discontinuation of treatment were as follows: complete response (five patients), resection (ten patients), progression (15 patients), adverse events (seven patients), and patient refusal (three patients). The overall response rate was 57.5%, resection rate was 25%, and liver resection rate was 15%. After a median follow-up of 31.4 months, the median time to treatment failure, PFS, and OS were 5.3, 13.3, and 38.9 months, respectively.
Conclusion: Although the median time to treatment failure was 5.3 months, the median PFS and OS were prolonged to 13.3 and 38.9 months, respectively. This may have resulted from the chemotherapy-free interval due to complete response in five patients and resection in ten patients.

Keywords: observational cohort study, metastatic colorectal cancer, XELOX plus bevacizumab, treatment continuity

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]